Topotecan in combination chemotherapy.

E. K. Rowinsky, Scott H Kaufmann

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The safety and efficacy of combination chemotherapy regimens containing topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I-targeting drug that has demonstrated significant antitumor activity in a wide range of human tumors, and various classes of antineoplastic agents is currently being evaluated. To date, phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide have been performed in adult and pediatric patients with solid tumors. Combination regimens consisting of topotecan combined with cytarabine, cyclophosphamide, and carboplatin also have been studied in patients with refractory leukemia. Myelosuppression, primarily neutropenia, has been the principal dose-limiting toxicity of these combination regimens. Major responses have been observed in many early studies. Both the toxicologic and antineoplastic effects have exhibited sequence dependence in preclinical and phase I studies, especially in evaluations of topotecan combined with alkylating agents and topoisomerase II-targeting drugs. At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number6 Suppl 20
StatePublished - Dec 1997
Externally publishedYes

Fingerprint

Topotecan
Combination Drug Therapy
Carboplatin
Drug Delivery Systems
Antineoplastic Agents
Type II DNA Topoisomerase
Type I DNA Topoisomerase
Alkylating Agents
Cytarabine
Etoposide
Neutropenia
Pharmaceutical Preparations
Doxorubicin
Cyclophosphamide
Cisplatin
Neoplasms
Leukemia
Pediatrics
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

Topotecan in combination chemotherapy. / Rowinsky, E. K.; Kaufmann, Scott H.

In: Seminars in Oncology, Vol. 24, No. 6 Suppl 20, 12.1997.

Research output: Contribution to journalArticle

Rowinsky, EK & Kaufmann, SH 1997, 'Topotecan in combination chemotherapy.', Seminars in Oncology, vol. 24, no. 6 Suppl 20.
Rowinsky, E. K. ; Kaufmann, Scott H. / Topotecan in combination chemotherapy. In: Seminars in Oncology. 1997 ; Vol. 24, No. 6 Suppl 20.
@article{14f828283d434504a143cc50d5629f0d,
title = "Topotecan in combination chemotherapy.",
abstract = "The safety and efficacy of combination chemotherapy regimens containing topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I-targeting drug that has demonstrated significant antitumor activity in a wide range of human tumors, and various classes of antineoplastic agents is currently being evaluated. To date, phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide have been performed in adult and pediatric patients with solid tumors. Combination regimens consisting of topotecan combined with cytarabine, cyclophosphamide, and carboplatin also have been studied in patients with refractory leukemia. Myelosuppression, primarily neutropenia, has been the principal dose-limiting toxicity of these combination regimens. Major responses have been observed in many early studies. Both the toxicologic and antineoplastic effects have exhibited sequence dependence in preclinical and phase I studies, especially in evaluations of topotecan combined with alkylating agents and topoisomerase II-targeting drugs. At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing.",
author = "Rowinsky, {E. K.} and Kaufmann, {Scott H}",
year = "1997",
month = "12",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 Suppl 20",

}

TY - JOUR

T1 - Topotecan in combination chemotherapy.

AU - Rowinsky, E. K.

AU - Kaufmann, Scott H

PY - 1997/12

Y1 - 1997/12

N2 - The safety and efficacy of combination chemotherapy regimens containing topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I-targeting drug that has demonstrated significant antitumor activity in a wide range of human tumors, and various classes of antineoplastic agents is currently being evaluated. To date, phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide have been performed in adult and pediatric patients with solid tumors. Combination regimens consisting of topotecan combined with cytarabine, cyclophosphamide, and carboplatin also have been studied in patients with refractory leukemia. Myelosuppression, primarily neutropenia, has been the principal dose-limiting toxicity of these combination regimens. Major responses have been observed in many early studies. Both the toxicologic and antineoplastic effects have exhibited sequence dependence in preclinical and phase I studies, especially in evaluations of topotecan combined with alkylating agents and topoisomerase II-targeting drugs. At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing.

AB - The safety and efficacy of combination chemotherapy regimens containing topotecan (Hycamtin; SmithKline Beecham Pharmaceuticals, Philadelphia, PA), a topoisomerase I-targeting drug that has demonstrated significant antitumor activity in a wide range of human tumors, and various classes of antineoplastic agents is currently being evaluated. To date, phase I and pharmacologic studies of topotecan combined with cisplatin, carboplatin, doxorubicin, and etoposide have been performed in adult and pediatric patients with solid tumors. Combination regimens consisting of topotecan combined with cytarabine, cyclophosphamide, and carboplatin also have been studied in patients with refractory leukemia. Myelosuppression, primarily neutropenia, has been the principal dose-limiting toxicity of these combination regimens. Major responses have been observed in many early studies. Both the toxicologic and antineoplastic effects have exhibited sequence dependence in preclinical and phase I studies, especially in evaluations of topotecan combined with alkylating agents and topoisomerase II-targeting drugs. At this juncture, additional phase I and II trials are required to evaluate the toxicity and efficacy of topotecan in combination with other agents and address critical issues related to optimal drug dosing and sequencing.

UR - http://www.scopus.com/inward/record.url?scp=0031302693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031302693&partnerID=8YFLogxK

M3 - Article

C2 - 9425957

AN - SCOPUS:0031302693

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 Suppl 20

ER -